Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04707248 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

Name: A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors — clinical trial record (NCT04707248)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1

SponsorDaiichi Sankyo

Started2020-12-22

View on ClinicalTrials.gov ↗

This clinical trial will evaluate raludotatug deruxtecan (R-DXd; DS-6000a) in participants with advanced renal cell carcinoma (RCC) and ovarian cancer (OVC). The main goals of this study will be to investigate the recommended dose of R-DXd that can be given safely to participants, assess the adverse events of R-DXd, and evaluate the effectiveness of R-DXd.

Amendment history 2 changes detected by DataLookout

2026-09-05

Primary completion pushed: 2026-04-30 → 2026-12-30

2026-09-05

Completion pushed: 2026-06-30 → 2026-12-30

Trial Details

NCT Number	NCT04707248
Lead Sponsor	Daiichi Sankyo Collaborators: Merck Sharp & Dohme LLC
Conditions	Renal Cell Carcinoma, Ovarian Tumor
Enrollment	179 participants
Start Date	2020-12-22
Primary Completion	2026-12-30 (estimated)
Study Completion	2026-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-09-04